AstraZeneca Inks $486M US Support For Covid-19 Antibody Cocktail, , on October 11, 2020 at 10:13 am

Financial News
By
On October 11, 2020
In Financial News
Tags:

AstraZeneca has secured $486m from the US Government for the development and supply of 100,000 doses of its potential AZD7442 antibody cocktail for the treatment of Covid-19.Under the current agreement, AstraZeneca (AZN) plans to supply up to 100,000 doses towards the end of 2020. In addition, the US government has an option to buy up to another 1 million doses in 2021.AZD7442, which is a combination of 2 long-acting antibodies (LAABs), will be evaluated in 2 Phase 3 clinical trials. The two AZD7442 trials, which will enroll over 6,000 adults testing the antibody cocktail for the prevention of Covid-19 at sites in and outside the US, are due to begin in the next few weeks. One trial will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12 months, in approximately 5,000 participants. The second trial will evaluate post-exposure prophylaxis and pre-emptive treatment in approximately 1,100 participants.Additional trials are planned with the enrollment of about 4,000 adults for the treatment of SARS-CoV-2 infections.“This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections,” AstraZeneca CEO Pascal Soriot said. “We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalisation, with a focus on helping the most vulnerable people.”The LAABs have been engineered with AstraZeneca’s proprietary half-life extension technology to increase the durability of the therapy for 6 to 12 months following a single administration. The combination of two LAABs is also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus, the company said.LAABs mimic natural antibodies and according to AstraZeneca have the potential to treat and prevent disease progression in patients already infected with the virus, as well as to be given as a preventative intervention prior to exposure to the virus. As such, a LAAB combination could be complementary to vaccines as a prophylactic treatment, for example for people for whom a vaccine may not be appropriate or to provide added protection for high-risk populations. It could also be used to treat people who have been infected, the company said.AZN shares have gained almost 10% this year as the drugmaker joined the list of companies engaged in the development of a potential coronavirus vaccine. The Phase 2/3 study of the AstraZeneca/Oxford vaccine candidate was last month put on hold after an adverse event in a single participant from the UK. The trial has been restarted in the UK but is still on hold in the US. (See AstraZeneca stock analysis on TipRanks)SVB Leerink analyst Andrew Berens recently reiterated a Buy rating on the stock with a $65 price target suggesting that the adverse event could have a broader impact and could cause near-term volatility in AstraZeneca’s shares as well as in the stock of other companies with Covid vaccine programs until the exact nature of the event is clear.As a result, Berens cautions that the overall speed of many of the programs could be affected as the investigation progresses and sponsors become more vigilant, as well as public sentiment regarding the safety of the vaccines once approved.Overall, AZN scores a Strong Buy consensus from the analyst community with 4 unanimous Buy ratings. Looking ahead, the $77.38 average analyst price target puts the upside potential at a promising 41% in the coming 12 months.Related News: CareDx Soars 15% As 3Q Revenue Outlook Surpasses Estimates BioNTech, Rentschler Partner For Covid-19 Vaccine Manufacturing Gilead Inks EU Supply Deal For 500,000 Remdesivir Doses More recent articles from Smarter Analyst: * Apple Allowed To Block Fortnite From App Store Amid Dispute * Microsoft or Apple: Which Tech Giant Is A Better Pick? * Air Canada Chops Transit Takeover Price By 74% Due To Covid-19 Crisis * Ameren Ramps Up Quarterly Dividend By 4%,

AstraZeneca Inks $486M US Support For Covid-19 Antibody CocktailAstraZeneca has secured $486m from the US Government for the development and supply of 100,000 doses of its potential AZD7442 antibody cocktail for the treatment of Covid-19.Under the current agreement, AstraZeneca (AZN) plans to supply up to 100,000 doses towards the end of 2020. In addition, the US government has an option to buy up to another 1 million doses in 2021.AZD7442, which is a combination of 2 long-acting antibodies (LAABs), will be evaluated in 2 Phase 3 clinical trials. The two AZD7442 trials, which will enroll over 6,000 adults testing the antibody cocktail for the prevention of Covid-19 at sites in and outside the US, are due to begin in the next few weeks. One trial will evaluate the safety and efficacy of AZD7442 to prevent infection for up to 12 months, in approximately 5,000 participants. The second trial will evaluate post-exposure prophylaxis and pre-emptive treatment in approximately 1,100 participants.Additional trials are planned with the enrollment of about 4,000 adults for the treatment of SARS-CoV-2 infections.“This agreement with the US government will help accelerate the development of our long-acting antibody combination which has the potential to provide immediate and long-lasting effect in both preventing and treating Covid-19 infections,” AstraZeneca CEO Pascal Soriot said. “We will be evaluating the LAAB combination in different settings from prophylaxis, to outpatient treatment to hospitalisation, with a focus on helping the most vulnerable people.”The LAABs have been engineered with AstraZeneca’s proprietary half-life extension technology to increase the durability of the therapy for 6 to 12 months following a single administration. The combination of two LAABs is also designed to reduce the risk of resistance developed by the SARS-CoV-2 virus, the company said.LAABs mimic natural antibodies and according to AstraZeneca have the potential to treat and prevent disease progression in patients already infected with the virus, as well as to be given as a preventative intervention prior to exposure to the virus. As such, a LAAB combination could be complementary to vaccines as a prophylactic treatment, for example for people for whom a vaccine may not be appropriate or to provide added protection for high-risk populations. It could also be used to treat people who have been infected, the company said.AZN shares have gained almost 10% this year as the drugmaker joined the list of companies engaged in the development of a potential coronavirus vaccine. The Phase 2/3 study of the AstraZeneca/Oxford vaccine candidate was last month put on hold after an adverse event in a single participant from the UK. The trial has been restarted in the UK but is still on hold in the US. (See AstraZeneca stock analysis on TipRanks)SVB Leerink analyst Andrew Berens recently reiterated a Buy rating on the stock with a $65 price target suggesting that the adverse event could have a broader impact and could cause near-term volatility in AstraZeneca’s shares as well as in the stock of other companies with Covid vaccine programs until the exact nature of the event is clear.As a result, Berens cautions that the overall speed of many of the programs could be affected as the investigation progresses and sponsors become more vigilant, as well as public sentiment regarding the safety of the vaccines once approved.Overall, AZN scores a Strong Buy consensus from the analyst community with 4 unanimous Buy ratings. Looking ahead, the $77.38 average analyst price target puts the upside potential at a promising 41% in the coming 12 months.Related News: CareDx Soars 15% As 3Q Revenue Outlook Surpasses Estimates BioNTech, Rentschler Partner For Covid-19 Vaccine Manufacturing Gilead Inks EU Supply Deal For 500,000 Remdesivir Doses More recent articles from Smarter Analyst: * Apple Allowed To Block Fortnite From App Store Amid Dispute * Microsoft or Apple: Which Tech Giant Is A Better Pick? * Air Canada Chops Transit Takeover Price By 74% Due To Covid-19 Crisis * Ameren Ramps Up Quarterly Dividend By 4%

,

Instant Quote

Enter the Stock Symbol.

Select the Exchange.

Select the Type of Security.

Please enter your First Name.

Please enter your Last Name.

Please enter your phone number.

Please enter your Email Address.

Please enter or select the Total Number of Shares you own.

Please enter or select the Desired Loan Amount you are seeking.

Please select the Loan Purpose.

Please select if you are an Officer/Director.

High West Capital Partners, LLC may only offer certain information to persons who are “Accredited Investors” and/or “Qualified Clients” as those terms are defined under applicable Federal Securities Laws. In order to be an “Accredited Investor” and/or a “Qualified Client”, you must meet the criteria identified in ONE OR MORE of the following categories/paragraphs numbered 1-20 below.

High West Capital Partners, LLC cannot provide you with any information regarding its Loan Programs or Investment Products unless you meet one or more of the following criteria. Furthermore, Foreign nationals who may be exempt from qualifying as a U.S. Accredited Investor are still required to meet the established criteria, in accordance with High West Capital Partners, LLC’s internal lending policies. High West Capital Partners, LLC will not provide information or lend to any individual and/or entity that does not meet one or more of the following criteria:

1) Individual with Net Worth in excess of $1.0 million. A natural person (not an entity) whose net worth, or joint net worth with his or her spouse, at the time of purchase exceeds $1,000,000 USD. (In calculating net worth, you may include your equity in personal property and real estate, including your principal residence, cash, short-term investments, stock and securities. Your inclusion of equity in personal property and real estate should be based on the fair market value of such property less debt secured by such property.)

2) Individual with $200,000 individual Annual Income. A natural person (not an entity) who had individual income of more than $200,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

3) Individual with $300,000 Joint Annual Income. A natural person (not an entity) who had joint income with his or her spouse in excess of $300,000 in each of the preceding two calendar years, and has a reasonable expectation of reaching the same income level in the current year.

4) Corporations or Partnerships. A corporation, partnership, or similar entity that has in excess of $5 million of assets and was not formed for the specific purpose of acquiring an interest in the Corporation or Partnership.

5) Revocable Trust. A trust that is revocable by its grantors and each of whose grantors is an Accredited Investor as defined in one or more of the other categories/paragraphs numbered herein.

6) Irrevocable Trust. A trust (other than an ERISA plan) that (a)is not revocable by its grantors, (b) has in excess of $5 million of assets, (c) was not formed for the specific purpose of acquiring an interest, and (d) is directed by a person who has such knowledge and experience in financial and business matters that such person is capable of evaluating the merits and risks of an investment in the Trust.

7) IRA or Similar Benefit Plan. An IRA, Keogh or similar benefit plan that covers only a single natural person who is an Accredited Investor, as defined in one or more of the other categories/paragraphs numbered herein.

8) Participant-Directed Employee Benefit Plan Account. A participant-directed employee benefit plan investing at the direction of, and for the account of, a participant who is an Accredited Investor, as that term is defined in one or more of the other categories/paragraphs numbered herein.

9) Other ERISA Plan. An employee benefit plan within the meaning of Title I of the ERISA Act other than a participant-directed plan with total assets in excess of $5 million or for which investment decisions (including the decision to purchase an interest) are made by a bank, registered investment adviser, savings and loan association, or insurance company.

10) Government Benefit Plan. A plan established and maintained by a state, municipality, or any agency of a state or municipality, for the benefit of its employees, with total assets in excess of $5 million.

11) Non-Profit Entity. An organization described in Section 501(c)(3) of the Internal Revenue Code, as amended, with total assets in excess of $5 million (including endowment, annuity and life income funds), as shown by the organization’s most recent audited financial statements.

12) A bank, as defined in Section 3(a)(2) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

13) A savings and loan association or similar institution, as defined in Section 3(a)(5)(A) of the Securities Act (whether acting for its own account or in a fiduciary capacity).

14) A broker-dealer registered under the Exchange Act.

15) An insurance company, as defined in Section 2(13) of the Securities Act.

16) A “business development company,” as defined in Section 2(a)(48) of the Investment Company Act.

17) A small business investment company licensed under Section 301 (c) or (d) of the Small Business Investment Act of 1958.

18) A “private business development company” as defined in Section 202(a)(22) of the Advisers Act.

19) Executive Officer or Director. A natural person who is an executive officer, director or general partner of the Partnership or the General Partner, and is an Accredited Investor as that term is defined in one or more of the categories/paragraphs numbered herein.

20) Entity Owned Entirely By Accredited Investors. A corporation, partnership, private investment company or similar entity each of whose equity owners is a natural person who is an Accredited Investor, as that term is defined in one or more of the categories/paragraphs numbered herein.

Please read the notice above and check the box below to continue.

Singapore

168 Robinson Road,
Capital Tower, Singapore 068912
+65 3105 1295

Taiwan

5th Floor, No. 1-8, Section 5, Zhongxiao East Road, Taipei

Hong Kong

R91, 3rd Floor,
Eton Tower, 8 Hysan Ave.
Causeway Bay, Hong Kong
+852 3002 4462

Australia

44 Martin Place, Sydney 2000 Australia
+02 8319 3232

Indonesia

Millennium Centennial Center, 38th Floor, Jl. Jend. Sudirman Kav. 25
Jakarta 12920, Indonesia

Market Coverage